Truly Technologies

Executive Summary

Truly Technologies, based in San Francisco, is a private bioprocessing company leveraging a proprietary osmotic pressure-driven membrane technology to isolate biomolecules with high yield and purity. Founded in 2017, the company addresses a critical bottleneck in biopharmaceutical manufacturing: the efficient concentration and purification of therapeutic nanoparticles, diagnostic biomarkers, and other biomolecules. Unlike traditional methods that often require complex multi-step processes, Truly's approach uses a semipermeable membrane and osmotic gradients to simultaneously concentrate and purify in a single step, reducing cost and time while improving scalability. This innovation has broad applications across digital health and AI-enabled diagnostics, positioning the company to serve the growing demand for advanced bioprocessing in precision medicine. Truly Technologies operates in a rapidly expanding market, with bioprocessing equipment expected to exceed $40 billion by 2030. The company's technology is particularly relevant for the purification of mRNA vaccines, gene therapies, and exosomes, where high purity and gentle handling are critical. With its simple, cost-effective solution, Truly has the potential to disrupt conventional chromatography and filtration methods. However, as a private company with limited public disclosures, detailed financials and commercial traction remain opaque. The team's expertise and the elegance of the technology suggest strong fundamentals, but execution risk remains given the competitive landscape and need for regulatory validation. Overall, Truly represents a promising but early-stage opportunity in the bioprocessing space.

Upcoming Catalysts (preview)

• Q4 2026Series A or B Funding Round Announcement70% success
• H1 2027Strategic Partnership with a Major Biopharma Company50% success
• Q2 2026Publication of Peer-Reviewed Data Demonstrating Technology Efficacy60% success